skip to main content

TAILORx — SCE Medical Oncology MCQ

Instant feedback + full explanation. One question, done properly.

HardBreast CancerTAILORxSCE Medical Oncology

A patient with metastatic KIT-mutant gastrointestinal stromal tumour progresses after an adequate trial of imatinib. Sequencing shows an acquired KIT ATP-binding-pocket mutation. What is the standard next systemic treatment?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: A — Sunitinib as second-line tyrosine-kinase inhibition

Sunitinib is the established second-line treatment after imatinib failure or intolerance in advanced GIST and has activity against several secondary KIT ATP-binding-pocket mutations. Later-line options include regorafenib and ripretinib. The other listed targeted and immune therapies do not address the dominant KIT-driven biology of conventional GIST.

Reference: https://www.nice.org.uk/guidance/conditions-and-diseases/cancer